Patents by Inventor Stephen Sazinsky

Stephen Sazinsky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-PD-1 antibodies and uses thereof
    Patent number: 11905329
    Abstract: Provided herein are various embodiments relating to antibodies. Some of the embodiments include antagonist antibodies that bind PD-1. Such antibodies can be used in methods to treat, for example, cancer.
    Type: Grant
    Filed: June 7, 2022
    Date of Patent: February 20, 2024
    Assignee: Jounce Therapeutics, Inc.
    Inventors: George Robert Mabry, III, Stephen Sazinsky
  • Anti-PD-1 Antibodies and Uses Thereof
    Publication number: 20230018445
    Abstract: Provided herein are various embodiments relating to antibodies. Some of the embodiments include antagonist antibodies that bind PD-1. Such antibodies can be used in methods to treat, for example, cancer.
    Type: Application
    Filed: June 7, 2022
    Publication date: January 19, 2023
    Applicant: Jounce Therapeutics, Inc.
    Inventors: George Robert Mabry, III, Stephen Sazinsky
  • Anti-PD-1 antibodies and uses thereof
    Patent number: 11384147
    Abstract: Provided herein are various embodiments relating to antibodies. Some of the embodiments include antagonist antibodies that bind PD-1. Such antibodies can be used in methods to treat, for example, cancer.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: July 12, 2022
    Assignee: Jounce Therapeutics, Inc.
    Inventors: George Robert Mabry, III, Stephen Sazinsky
  • Gene Signatures for Determining ICOS Expression
    Publication number: 20210340256
    Abstract: Gene expression signatures correlating to ICOS expression levels are provided. Methods of treatment comprising determining ICOS expression levels using gene signatures in patients and administering anti-ICOS antibodies are also provided.
    Type: Application
    Filed: February 5, 2021
    Publication date: November 4, 2021
    Applicant: Jounce Therapeutics, Inc.
    Inventors: Jason Windham Reeves, Igor Feldman, Christopher Harvey, Sriram Sathyanarayanan, Heather Hirsch, Lauren Pepper MacKenzie, Amit Deshpande, Stephen Sazinsky, Jennifer S. Michaelson, Kutlu Goksu Elpek
  • Antibodies to ICOS
    Publication number: 20210171635
    Abstract: Provided herein are various embodiments relating to antibodies. Some of the embodiments include agonist antibodies that bind ICOS. Such antibodies can be used in methods to treat, for example, cancer.
    Type: Application
    Filed: September 16, 2020
    Publication date: June 10, 2021
    Applicant: Jounce Therapeutics, Inc.
    Inventors: Stephen Sazinsky, Jennifer S. Michaelson, Sriram Sathyanarayanan, Kutlu Goksu Elpek
  • Gene signatures for determining ICOS expression
    Patent number: 10968277
    Abstract: Gene expression signatures correlating to ICOS expression levels are provided. Methods of treatment comprising determining ICOS expression levels using gene signatures in patients and administering anti-ICOS antibodies are also provided.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: April 6, 2021
    Assignee: Jounce Therapeutics, Inc.
    Inventors: Jason Windham Reeves, Igor Feldman, Christopher Harvey, Sriram Sathyanarayanan, Heather Hirsch, Lauren Pepper MacKenzie, Amit Deshpande, Stephen Sazinsky, Jennifer S. Michaelson, Kutlu Goksu Elpek
  • Anti-PD-1 Antibodies and Uses Thereof
    Publication number: 20200399374
    Abstract: Provided herein are various embodiments relating to antibodies. Some of the embodiments include antagonist antibodies that bind PD-1. Such antibodies can be used in methods to treat, for example, cancer.
    Type: Application
    Filed: April 10, 2020
    Publication date: December 24, 2020
    Applicant: Jounce Therapeutics, Inc.
    Inventors: George Robert Mabry, III, Stephen Sazinsky
  • Antibodies to PD-1 and uses thereof
    Patent number: 10654929
    Abstract: Provided herein are various embodiments relating to antibodies. Some of the embodiments include antagonist antibodies that bind PD-1. Such antibodies can be used in methods to treat, for example, cancer.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: May 19, 2020
    Assignee: Jounce Therapeutics, Inc.
    Inventors: George Robert Mabry, III, Stephen Sazinsky
  • Antibodies to ICOS
    Patent number: 10570203
    Abstract: Provided herein are various embodiments relating to antibodies. Some of the embodiments include agonist antibodies that bind ICOS. Such antibodies can be used in methods to treat, for example, cancer.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: February 25, 2020
    Assignee: Jounce Therapeutics, Inc.
    Inventors: Stephen Sazinsky, Jennifer S. Michaelson, Sriram Sathyanarayanan, Kutlu Goksu Elpek
  • GENE SIGNATURES FOR DETERMINING ICOS EXPRESSION
    Publication number: 20180371091
    Abstract: Gene expression signatures correlating to ICOS expression levels are provided. Methods of treatment comprising determining ICOS expression levels using gene signatures in patients and administering anti-ICOS antibodies are also provided.
    Type: Application
    Filed: October 21, 2016
    Publication date: December 27, 2018
    Applicant: Jounce Therapeutics, Inc.
    Inventors: Jason Windham Reeves, Igor Feldman, Christopher Harvey, Sriram Sathyanarayanan, Heather Hirsch, Lauren Pepper MacKenzie, Amit Deshpande, Stephen Sazinsky, Jennifer S. Michaelson, Kutlu Gosku Elpek
  • Antibodies to ICOS
    Publication number: 20180355041
    Abstract: Provided herein are various embodiments relating to antibodies. Some of the embodiments include agonist antibodies that bind ICOS. Such antibodies can be used in methods to treat, for example, cancer.
    Type: Application
    Filed: June 20, 2018
    Publication date: December 13, 2018
    Applicant: Jounce Therapeutics, Inc.
    Inventors: Stephen Sazinsky, Jennifer S. Michaelson, Sriram Sathyanarayanan, Kutlu Goksu Elpek
  • Antibodies to ICOS
    Patent number: 10023635
    Abstract: Provided herein are various embodiments relating to antibodies. Some of the embodiments include agonist antibodies that bind ICOS. Such antibodies can be used in methods to treat, for example, cancer.
    Type: Grant
    Filed: March 22, 2016
    Date of Patent: July 17, 2018
    Assignee: Jounce Therapeutics, Inc.
    Inventors: Stephen Sazinsky, Jennifer S. Michaelson, Sriram Sathyanarayanan, Kutlu Goksu Elpek
  • ANTIBODIES TO PD-1 AND USES THEREOF
    Publication number: 20180118829
    Abstract: Provided herein are various embodiments relating to antibodies. Some of the embodiments include antagonist antibodies that bind PD-1. Such antibodies can be used in methods to treat, for example, cancer.
    Type: Application
    Filed: November 1, 2017
    Publication date: May 3, 2018
    Applicant: Jounce Therapeutics, Inc.
    Inventors: George Robert Mabry, III, Stephen Sazinsky
  • ANTIBODIES TO ICOS
    Publication number: 20160304610
    Abstract: Provided herein are various embodiments relating to antibodies. Some of the embodiments include agonist antibodies that bind ICOS. Such antibodies can be used in methods to treat, for example, cancer.
    Type: Application
    Filed: March 22, 2016
    Publication date: October 20, 2016
    Inventors: Stephen Sazinsky, Jennifer S. Michaelson, Sriram Sathyanarayanan, Kutlu Goksu Elpek
  • ANTIBODIES THAT INHIBIT TIM-3:LILRB2 INTERACTIONS AND USES THEREOF
    Publication number: 20160200815
    Abstract: Provided herein are embodiments relating to therapeutic applications of antibodies that modulate; e.g., inhibit the interaction of TIM-3 and LILRB2 antibodies. In some embodiments, the antibodies bind TIM-3. In some embodiments the antibodies bind LILRB2. Modulation of the interaction of TIM-3 and LILRB2 stimulates the release of pro-inflammatory cytokines; e.g., myeloid-associated pro-inflammatory cytokines.
    Type: Application
    Filed: January 4, 2016
    Publication date: July 14, 2016
    Inventors: Igor FELDMAN, Tatiana NOVOBRANTSEVA, Jamie WONG, Ryan PHENNICIE, Stephen Sazinsky, Sriram Sathyanarayanan